Bibliography
- Bazalo GR, Joshi AV, Germak J. Comparison of human growth hormone products’ cost in pediatric and adult patients. A budgetary impact model. Manag Care 2007;16(9):45-51
- Smith SL, Hindmarsh PC, Brook CG. Compliance with growth hormone treatment – are they getting it? Arch Dis Child 1993;68:91-3
- Fuchs GS, Mikkelsen S, Knudsen TK, et al. Ease of use and acceptability of a new pen device for the administration of growth hormone therapy in pediatric patients: an open-label, uncontrolled usability test. Clin Ther 2009;31(12):2906-14
- Dumas H, Panayiotopoulos P, Parker D, et al. Understanding and meeting the needs of those using growth hormone injection devices. BMC Endocr Disord 2006;6:5
- Shine B, Musial W, Owens L, et al. Patient and parent preference for growth hormone products. Am J Health Syst Pharm 2003;60(1):89-90
- Pfützner A, Hartmann K, Winter F, et al. Intuitiveness, ease of use, and preference of a prefilled growth hormone injection pen: a noninterventional, randomized, open-label, crossover, comparative usability study of three delivery devices in growth hormone-treated pediatric patients. Clin Ther 2010;32(11):1918-34
- Kappelgaard AM, Mikkelsen S, Knudsen TK, et al. Patient preference for a new growth hormone injection device: results of an open-label study in Japanese pediatric patients. J Pediatr Endocrinol Metab 2011;24(7–8):489-96
- Dahlgren J. Easypod: a new electronic injection device for growth hormone. Expert Rev Med Devices 2008;5(3):297-304
- Kappelgaard AM, Hansen NÅ. Comparison of injection dose force, accuracy and precision among three growth hormone injection devices. Expert Rev Med Devices 2013;10(3):321-7
- Pollock RF, Qian Y, Wisniewski T, et al. Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis. Med Devices (Auckl) 2013;6:107-14
- Höybye C, Sävendahl L, Christesen HT, et al. The NordiNet® International Outcome Study and NovoNet® ANSWER Program®: rationale, design, and methodology of two international pharmacoepidemiological registry-based studies monitoring long-term clinical and safety outcomes of growth hormone therapy (Norditropin®). Clin Epidemiol 2013;5:119-27
- Cook DM, Rose SR. A review of guidelines for use of growth hormone in pediatric and transition patients. Pituitary 2012;15(3):301-10
- Cook DM, Yuen KC, Biller BM, et al. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients - 2009 update. Endocr Pract 2009;15(Suppl 2):1-29
- Kapoor RR, Burke SA, Sparrow SE, et al. Monitoring of concordance in growth hormone therapy. Arch Dis Child 2008;93:147-8
- Cutfield WS, Derraik JGB, Gunn AJ, et al. Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS One 2011;6:e16223
- Desrosiers P, O’Brien F, Blethen S. Patient outcomes in the GHMonitor: the effect of delivery device on compliance and growth. Pediatr Endocrinol Rev 2005;2(Suppl 3):327-31
- Radovick S, Divall S. Approach to the growth hormone-deficient child during transition to adulthood. J Clin Endocrinol Metab 2007;92(4):1195-200
- Mauras N, Attie KM, Reiter EO, et al. High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. Genentech, Inc., Cooperative Study Group. J Clin Endocrinol Metab 2000;85(10):3653-60
- van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, et al. Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab 2003;88(3):1119-25
- Sas TC, de Ridder MA, Wit JM, et al. Adult height in children with growth hormone deficiency: a randomized, controlled, growth hormone dose-response trial. Horm Res Paediatr 2010;74(3):172-81
- Kappelgaard AM, Kiyomi F, Horikawa R, et al. The impact of long-term growth hormone treatment on metabolic parameters in Japanese patients with short stature born small for gestational age. Horm Res Paediatr 2014;81(4):272-9
- Pfizer, Inc. Growth hormone delivery device for use with genotropin® lyophilized powder (somatropin [rDNAorigin] for injection). Available from: http://www.genotropin.com/sites/g/files/g10002911/f/201306/Genotropin_Pen_5_Insturctions_for_Use.pdf [Last accessed 25 November 2014]
- Genentech, Inc. Nutropin AQ® NuSpin™ 10 Instructions for use. Available from: http://www.nutropin.com/hcp/sites/nutropin.com/files/pdfs/nuspin-10-instructions-for-use.pdf [Last accessed 2 December 2014]